ATOPIC DERMATITIS EVALUATING THE EFFICACY OF COMPLEX THERAPY AIMED AT RESTORING THE SKIN PROTECTIVE BARRIER

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease affecting up to 20% of children and 3% of adults globally. Epidermal barrier dysfunction - driven by filaggrin gene mutations, ceramide deficiency, and Th2-skewed immune dysregulation - constitutes the primary pathogenic event. This review evaluates the clinical efficacy of complex barrier-restorative therapies including physiological lipid emollients, dupilumab, topical JAK inhibitors, and combined protocols, using quantitative TEWL, EASI, and SCORAD metrics as outcome parameters.

Hali tarjima qilinmagan